1,986 Shares in Cencora, Inc. $COR Acquired by Stevens Capital Management LP

Stevens Capital Management LP purchased a new stake in Cencora, Inc. (NYSE:COR) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 1,986 shares of the company’s stock, valued at approximately $671,000.

A number of other institutional investors and hedge funds have also bought and sold shares of COR. Oakworth Capital Inc. acquired a new position in Cencora during the 4th quarter worth about $26,000. Archer Investment Corp raised its position in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares during the last quarter. IAG Wealth Partners LLC acquired a new position in shares of Cencora in the third quarter worth approximately $30,000. Cloud Capital Management LLC bought a new stake in Cencora in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC acquired a new stake in Cencora during the 3rd quarter valued at approximately $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of Cencora stock opened at $305.89 on Wednesday. The business has a 50-day simple moving average of $332.27 and a 200 day simple moving average of $343.21. Cencora, Inc. has a one year low of $271.00 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The firm has a market capitalization of $59.50 billion, a price-to-earnings ratio of 36.77, a PEG ratio of 1.42 and a beta of 0.64.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.80 by ($0.05). Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts anticipate that Cencora, Inc. will post 17.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on COR shares. Barclays lifted their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. JPMorgan Chase & Co. increased their price target on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Morgan Stanley set a $380.00 target price on Cencora in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company lifted their target price on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $398.17.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.